Abstracts tagged "Allopurinol"

Abstract Number: 1875 • 2014 ACR/ARHP Annual Meeting
Can Allopurinol Survival Impact Reverse Depending on Patients’ Characteristics? a Propensity-Score-Based Subgroup Analysis
Na Lu¹, Hyon K. Choi², Maureen Dubreuil^3,4, Qiong Louie-Gao⁵ and Yuqing Zhang¹, ¹Boston University School of Medicine, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Rheumatology, Boston VA HealthCare System, Boston, MA, ⁵Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Several studies have reported that allopurinol use is associated with a decreased risk of death or cardiovascular outcomes. While these studies reported the overall…
Abstract Number: 1808 • 2014 ACR/ARHP Annual Meeting
Role of HLA-B*5801 Genetic Testing and a Safety Programme When Initiating Allopurinol Therapy for Chronic Gout Management: A Cost-Effectiveness Analysis
Di Dong¹, Wei Chuen Tan-Koi^2,3, Gim Gee Teng^4,5, Eric Finkelstein⁶ and Cynthia Sung^7,8, ¹Health Services and Systems Research Program, Duke-NUS Graduate Medical School, Singapore, Singapore, ²Vigilance & Compliance Branch, Health Sciences Authority, Singapore, Singapore, Singapore, ³Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, ⁴Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁵Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, ⁶Health Services and Systems Research Program, Duke-NUS Graduate Medical School, Singapore., Singapore, Singapore, ⁷Vigilance & Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore, Singapore, Singapore, ⁸Emerging Infectious Diseases Program, Duke-NUS Graduate Medical School, Singapore., Singapore, Singapore
Background/Purpose To conduct a cost-effectiveness analysis from a health system perspective of various strategies in managing chronic gout to mitigate risk of allopurinol-induced Stevens-Johnson Syndrome…
Abstract Number: 1214 • 2014 ACR/ARHP Annual Meeting
Oxidative Stress from Use of Allopurinol – Is There a Reason for Patients with Gout to Take Vitamin C?
Lisa K. Stamp¹, Peter T. Chapman², John L. O'Donnell³, Irada Khalilova⁴, Rufus Turner⁴ and Anthony Kettle⁴, ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, ³Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, ⁴Pathology, University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose During acute gout attacks neutrophils are activated and release a number of pro-inflammatory cytokines and enzymes. One of these enzymes is myeloperoxidase (MPO), which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].